Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/PLK1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/PLK1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/PLK1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/PLK1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/PLK1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00330451 | Oral cavity | OSCC | regulation of sister chromatid segregation | 47/7305 | 72/18723 | 5.69e-06 | 6.33e-05 | 47 |
GO:19058181 | Oral cavity | OSCC | regulation of chromosome separation | 47/7305 | 72/18723 | 5.69e-06 | 6.33e-05 | 47 |
GO:003001016 | Oral cavity | OSCC | establishment of cell polarity | 82/7305 | 143/18723 | 6.56e-06 | 7.24e-05 | 82 |
GO:19040293 | Oral cavity | OSCC | regulation of cyclin-dependent protein kinase activity | 60/7305 | 98/18723 | 6.90e-06 | 7.56e-05 | 60 |
GO:00000793 | Oral cavity | OSCC | regulation of cyclin-dependent protein serine/threonine kinase activity | 58/7305 | 94/18723 | 6.92e-06 | 7.57e-05 | 58 |
GO:00902244 | Oral cavity | OSCC | regulation of spindle organization | 29/7305 | 39/18723 | 7.81e-06 | 8.43e-05 | 29 |
GO:00109651 | Oral cavity | OSCC | regulation of mitotic sister chromatid separation | 43/7305 | 65/18723 | 8.50e-06 | 9.06e-05 | 43 |
GO:00315704 | Oral cavity | OSCC | DNA integrity checkpoint | 72/7305 | 123/18723 | 8.77e-06 | 9.31e-05 | 72 |
GO:00705077 | Oral cavity | OSCC | regulation of microtubule cytoskeleton organization | 84/7305 | 148/18723 | 8.80e-06 | 9.33e-05 | 84 |
GO:00300711 | Oral cavity | OSCC | regulation of mitotic metaphase/anaphase transition | 40/7305 | 60/18723 | 1.32e-05 | 1.33e-04 | 40 |
GO:00616405 | Oral cavity | OSCC | cytoskeleton-dependent cytokinesis | 60/7305 | 100/18723 | 1.69e-05 | 1.67e-04 | 60 |
GO:0010389 | Oral cavity | OSCC | regulation of G2/M transition of mitotic cell cycle | 57/7305 | 94/18723 | 1.75e-05 | 1.71e-04 | 57 |
GO:00000774 | Oral cavity | OSCC | DNA damage checkpoint | 67/7305 | 115/18723 | 2.20e-05 | 2.08e-04 | 67 |
GO:00447841 | Oral cavity | OSCC | metaphase/anaphase transition of cell cycle | 42/7305 | 65/18723 | 2.57e-05 | 2.39e-04 | 42 |
GO:00447744 | Oral cavity | OSCC | mitotic DNA integrity checkpoint | 52/7305 | 85/18723 | 2.86e-05 | 2.64e-04 | 52 |
GO:00447734 | Oral cavity | OSCC | mitotic DNA damage checkpoint | 50/7305 | 81/18723 | 2.87e-05 | 2.64e-04 | 50 |
GO:0051783 | Oral cavity | OSCC | regulation of nuclear division | 78/7305 | 139/18723 | 3.13e-05 | 2.86e-04 | 78 |
GO:00901695 | Oral cavity | OSCC | regulation of spindle assembly | 20/7305 | 25/18723 | 3.47e-05 | 3.11e-04 | 20 |
GO:20012512 | Oral cavity | OSCC | negative regulation of chromosome organization | 52/7305 | 86/18723 | 4.50e-05 | 3.84e-04 | 52 |
GO:19020991 | Oral cavity | OSCC | regulation of metaphase/anaphase transition of cell cycle | 40/7305 | 63/18723 | 7.19e-05 | 5.67e-04 | 40 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PLK1 | SNV | Missense_Mutation | | c.732G>C | p.Leu244Phe | p.L244F | P53350 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-A8-A094-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PLK1 | SNV | Missense_Mutation | | c.658C>G | p.Pro220Ala | p.P220A | P53350 | protein_coding | deleterious(0.01) | probably_damaging(1) | TCGA-A8-A09G-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
PLK1 | SNV | Missense_Mutation | novel | c.1729G>C | p.Ala577Pro | p.A577P | P53350 | protein_coding | tolerated(0.19) | probably_damaging(0.937) | TCGA-AR-A1AP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD |
PLK1 | insertion | Frame_Shift_Ins | novel | c.751_752insCATACGTCTTTGCAGTGGGGTTTTTTCAAATGAAAAC | p.Phe251SerfsTer14 | p.F251Sfs*14 | P53350 | protein_coding | | | TCGA-A2-A0CU-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
PLK1 | insertion | Nonsense_Mutation | novel | c.1150_1151insCAGTGGCGCGCAGGCTTTTGTAACGT | p.Val384AlafsTer8 | p.V384Afs*8 | P53350 | protein_coding | | | TCGA-A8-A0A6-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | epirubicin | CR |
PLK1 | insertion | In_Frame_Ins | novel | c.694_695insACAGCATTTTCTTAGGGCAGCCCTTTGCTGGGC | p.Val232delinsAspSerIlePheLeuGlyGlnProPheAlaGlyLeu | p.V232delinsDSIFLGQPFAGL | P53350 | protein_coding | | | TCGA-AN-A03Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PLK1 | deletion | Frame_Shift_Del | novel | c.403delC | p.Arg135GlyfsTer14 | p.R135Gfs*14 | P53350 | protein_coding | | | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD |
PLK1 | SNV | Missense_Mutation | rs749527952 | c.977N>T | p.Ser326Leu | p.S326L | P53350 | protein_coding | tolerated(0.07) | benign(0.117) | TCGA-EA-A50E-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
PLK1 | SNV | Missense_Mutation | | c.1736G>A | p.Arg579Gln | p.R579Q | P53350 | protein_coding | deleterious(0.01) | probably_damaging(0.994) | TCGA-5M-AAT6-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
PLK1 | SNV | Missense_Mutation | | c.596C>T | p.Thr199Ile | p.T199I | P53350 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-A6-6780-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5347 | PLK1 | TRANSCRIPTION FACTOR, KINASE, TUMOR SUPPRESSOR, SERINE THREONINE KINASE, ENZYME, DRUGGABLE GENOME | | DNDI1417055 | CHEMBL1486366 | |
5347 | PLK1 | TRANSCRIPTION FACTOR, KINASE, TUMOR SUPPRESSOR, SERINE THREONINE KINASE, ENZYME, DRUGGABLE GENOME | | NSC-7387 | CHEMBL119878 | |
5347 | PLK1 | TRANSCRIPTION FACTOR, KINASE, TUMOR SUPPRESSOR, SERINE THREONINE KINASE, ENZYME, DRUGGABLE GENOME | | DNDI1417601 | CHEMBL1503729 | |
5347 | PLK1 | TRANSCRIPTION FACTOR, KINASE, TUMOR SUPPRESSOR, SERINE THREONINE KINASE, ENZYME, DRUGGABLE GENOME | | PLK-1 INHIBITOR | | |
5347 | PLK1 | TRANSCRIPTION FACTOR, KINASE, TUMOR SUPPRESSOR, SERINE THREONINE KINASE, ENZYME, DRUGGABLE GENOME | | LANSOPRAZOLE | LANSOPRAZOLE | |
5347 | PLK1 | TRANSCRIPTION FACTOR, KINASE, TUMOR SUPPRESSOR, SERINE THREONINE KINASE, ENZYME, DRUGGABLE GENOME | | 2-ANILINOPYRIDINE | CHEMBL555260 | |
5347 | PLK1 | TRANSCRIPTION FACTOR, KINASE, TUMOR SUPPRESSOR, SERINE THREONINE KINASE, ENZYME, DRUGGABLE GENOME | | SOTRASTAURIN | SOTRASTAURIN | |
5347 | PLK1 | TRANSCRIPTION FACTOR, KINASE, TUMOR SUPPRESSOR, SERINE THREONINE KINASE, ENZYME, DRUGGABLE GENOME | | DNDI1417400 | CHEMBL1362503 | |
5347 | PLK1 | TRANSCRIPTION FACTOR, KINASE, TUMOR SUPPRESSOR, SERINE THREONINE KINASE, ENZYME, DRUGGABLE GENOME | | PRODINE HYDROCHLORIDE | ALPHAPRODINE HYDROCHLORIDE | |
5347 | PLK1 | TRANSCRIPTION FACTOR, KINASE, TUMOR SUPPRESSOR, SERINE THREONINE KINASE, ENZYME, DRUGGABLE GENOME | | GW843682X | GW843682X | |